{"id":491043,"date":"2021-05-11T07:34:06","date_gmt":"2021-05-11T11:34:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-announces-first-quarter-2021-financial-results-and-business-update\/"},"modified":"2021-05-11T07:34:06","modified_gmt":"2021-05-11T11:34:06","slug":"fusion-pharmaceuticals-announces-first-quarter-2021-financial-results-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-announces-first-quarter-2021-financial-results-and-business-update\/","title":{"rendered":"Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022<\/i>\n <\/p>\n

\n Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions <\/i>\n <\/p>\n

\n HAMILTON, ON<\/span> and BOSTON<\/span>, May 11, 2021<\/span> \/PRNewswire\/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021<\/span> and provided an update on clinical and corporate developments.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Fusion
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We continue to advance our Phase 1 study of FPI-1434,” said Chief Executive Officer John Valliant<\/span>, Ph.D. “In anticipation of data and determination of a recommended Phase 2 dose in the first half of 2022, we are amending the study protocol to define tumor-specific cohorts based upon IGF-1R expression and tumor uptake as seen to date in the Phase 1 study.”<\/p>\n

Dr. Valliant continued, “In parallel, we are building a diverse pipeline of alpha-emitting radiopharmaceuticals. We expect to file our investigational new drug (IND) application for FPI-1966 in the second quarter of this year. In addition, we recently completed the acquisition of IPN-1087, a first-in-class small molecule beta-emitting radiopharmaceutical targeting neurotensin receptor 1 (NTSR1), which is expressed on multiple solid tumors and which we plan to convert into alpha-emitting FPI-2059. These programs demonstrate the depth and versatility of Fusion’s radiopharmaceutical platform and our potential to treat a broad array of solid tumors with high unmet medical need.<\/p>\n

“Evidenced by our recent presentations at the American Association for Cancer Research (AACR) Annual Meeting, we are excited about the potential to evaluate Fusion’s TATs in combination with the latest generation of cancer therapies, including checkpoint inhibitors and DNA damage response inhibitors (DDRis). Our recently announced collaborations with Merck and AstraZeneca enable us to explore these combination therapies and highlight the growing interest in TAT therapies.” <\/p>\n

\n Recent Highlights and Future Milestones<\/b>\n <\/p>\n

Corporate Updates<\/p>\n